Skip to main navigation
Telix Pharmaceuticals Limited Logo
  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Financials
    • Half-year & Quarterly Results
    • Annual Reports & AGMs
    • ASX Announcements
    • SEC Filings
  • Pipeline
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Board & Management
    • Documents & Charters
    • Sustainability
  • Resources
    • Shareholder Information
    • Investor Resources
    • Email Alerts
    • Contact Us

ASX Announcements

Date Title
07 Apr 2026
Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
02 Apr 2026
Ceasing to be a substantial holder
02 Apr 2026
Telix Appoints David Gill as Non-Executive Director
20 Mar 2026
Change in substantial holding
20 Mar 2026
Notification regarding unquoted securities - TLX
18 Mar 2026
Appendix 3Y Change in Director Interests - C Behrenbruch
18 Mar 2026
Notification of cessation of securities - TLX
17 Mar 2026
Becoming a substantial holder
16 Mar 2026
Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging
12 Mar 2026
Becoming a substantial holder from CGF
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 37

Subscribe to our Email Alerts

©2026 Telix Pharmaceuticals Limited.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. This website is intended for corporate communication and investor relations purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Forward Looking Statements
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube
Search Investors